Ignite Creation Date:
2024-05-06 @ 6:41 PM
Last Modification Date:
2025-12-17 @ 6:55 AM
Study NCT ID:
NCT05744297
Status:
None
Last Update Posted:
2023-05-12 00:00:00
First Post:
2023-02-02 00:00:00
Brief Title:
NLRP3 Inflammasome Activation Among Patients During Acute Gout Flares
Sponsor:
Centre Hospitalier Saint Joseph Saint Luc de Lyon
Organization:
Centre Hospitalier Saint Joseph Saint Luc de Lyon
Study Overview
Official Title:
NLRP3 Inflammasome Activation Among Patients During Acute Gout Flares
Status:
None
Status Verified Date:
2023-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ActiNG
Brief Summary:
Blood and synovial fluid will be obtained from remainder of patients' samples during an acute gout flares. White blood cells will be isolated and NLRP3 inflammasome activation will be assessed. Then, NLRP3 inflammasome inhibitors will be tested on cells with NLRP3 inflammasome activity.
Detailed Description:
Blood and synovial fluid will be obtained from remainder of patients samples during an acute gout flares White blood cells will be isolated and NLRP3 inflammasome activation will be assessed Then NLRP3 inflammasome inhibitors will be tested on cells with NLRP3 inflammasome activity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None